2 weeks Ago By ABMN Staff
Shares of Marinus Pharmaceuticals, Inc. ( NASDAQ:MRNS – Get Free Report ) have been given an average rating of “Moderate Buy” by the eight research firms that are currently covering the stock, MarketBeat.com reports.
Three analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $8.83.
A number of research analysts have weighed in on MRNS shares. Truist Financial reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Marinus Pharmaceuticals in a report on Tuesday, June 18th.
Cantor Fitzgerald restated an “overweight” rating and issued a $13.00 price target on shares of Marinus Pharmaceuticals in a research note on Tuesday, September 24th. HC Wainwright reaffirmed a “buy” rating and issued a $11.
00 price target on shares of Marinus Pharmaceuticals in a report on Wednesday, August 14th. JMP Securities reissued a “market outperform” rating and issued a $10.00 price objective on shares of Marinus Pharmaceuticals in a report on Monday, September 23rd.
Finally, StockNews.com downgraded Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday. Read Our Latest Stock Report on MRNS Hedge Funds Weigh In On Marinus Pharmaceuticals Marinus Pharmaceuticals Stock Up 6.
4 % Marinus Pharmaceuticals stock opened at $1.84 on Monday. The business’s 50-day moving average price is $1.
41 and its 200 day moving average price is $2.57. The company has a quick ratio of 2.
15, a current ratio of 2.28 and a debt-to-equity ratio of 5.68.
The firm has a market cap of $101.08 million, a price-to-earnings ratio of -0.70 and a beta of 1.
13. Marinus Pharmaceuticals has a 52 week low of $1.05 and a 52 week high of $11.
26. Marinus Pharmaceuticals ( NASDAQ:MRNS – Get Free Report ) last issued its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported ($0.
60) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.01).
Marinus Pharmaceuticals had a negative return on equity of 7,831.35% and a negative net margin of 493.14%.
The firm had revenue of $8.06 million for the quarter, compared to analyst estimates of $9.05 million.
During the same period in the previous year, the business earned ($0.61) EPS. As a group, sell-side analysts anticipate that Marinus Pharmaceuticals will post -1.
88 earnings per share for the current year. Marinus Pharmaceuticals Company Profile ( Get Free Report Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.
Recommended Stories Receive News & Ratings for Marinus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marinus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter ..
